We are pleased to announce the opening of WuXi STA’s new sterile lipid nanoparticle formulation (LNP) development and manufacturing facility at its Wuxi city campus.
This new facility integrates multi-channel chip, micro-mixer system, and complex preparation system into a multi-channel micro-mixer core LNP manufacturing platform, offering significant advantages in drug-loading, liposome particle size control, and encapsulation efficiency.
As a premier Contract Research, Development, and Manufacturing Organization (CRDMO), WuXi STA’s integrated drug product platform offers a full spectrum of services. WuXi STA will continue to expand its CRDMO platform’s capacity and capabilities to enable partners to accelerate more innovative drugs to market for patients worldwide.
Read the full press release here: https://bit.ly/3xc9wX9